Only show
results from:

Sort results by:

Display preferences
39 results sorted by relevancy Results per page:
Gilead Sciences Presents 48-Week Phase II Safety and Efficacy Results For Once-Daily Anti-HIV Agent, Tenofovir DF.
PR Newswire; Apr 17, 2000; 700+ Words ...PRNewswire/ -- Gilead Sciences, Inc...this study, 48 weeks of treatment...seen at 24 weeks, as previously...Design The 48-week double-blind...through 48 weeks, no patients...Study 902 as a 48-week trial to gain...Officer of Gilead. "These...
Gilead Sciences Presents Clinical Data Demonstrating Activity of PREVEON in Patients With 3TC and AZT Resistant HIV.
Business Wire; Jun 25, 1998; 700+ Words ...25, 1998--Gilead Sciences (NASDAQ:GILD...PREVEON for 24 weeks was not associated...presented this week at the "Second...of Virology at Gilead Sciences. The...observed at 24 weeks in patients with...M184V mutation present at baseline...receiving PREVEON for 48 ...
Gilead Sciences presents highly statistically significant efficacy data from Phase II III pivotal study of VISTIDE(TM) in patients with CMV retinitis.
Business Wire; Jan 31, 1995; 700+ Words ...Jan. 31, 1995--Gilead Sciences, Inc. (NASDAQ...efficacy data from a 48-patient Phase II...clinical affairs for Gilead Sciences, Inc...data collected from 48 patients enrolled...intravenously once per week for two weeks and then twice per...
United States : Gilead Sciences to present Viread Phase III clinical trial data.
TendersInfo; Nov 2, 2009; 700+ Words ...Byline: pinto03 Gilead Sciences, Inc. (Nasdaq...year (144-week) open label...being held this week in Boston, October...for up to 144 weeks experienced sustained...patients up to 144 weeks of treatment...on earlier (48-week) results from...
Gilead Sciences Announces Acceptance of Late Breaker Abstract At Upcoming Scientific Conference.
Business Wire; Sep 13, 1999; 700+ Words ...be Presented Gilead Sciences (Nasdaq:GILD...Colorado, will present preliminary 24-week safety and efficacy...September 27 at 12:48 p.m. in Late...No. 93.1. Gilead products and...Exhibit Hall Gilead Sciences Renal...Controlled 12:48 p.m. Room...
Gilead Sciences Announces Acceptance of Late Breaker Abstract At Upcoming ICAAC Meeting; Forty-Eight Week Data From Phase III Study of Adefovir Dipivoxil 10 mg to be Presented.
Business Wire; Sep 6, 2001; 700+ Words ...Sept. 6, 2001 Gilead Sciences (Nasdaq:GILD) today announced that 48-week clinical data from a...were summarized in a Gilead press release issued...Hospital, Singapore, will present 48-week safety and efficacy...
Gilead Sciences Announces Acceptance of Viread Late Breaker Abstracts At Upcoming 14th International AIDS Conference.
Business Wire; Jun 18, 2002; 700+ Words ...Forty-eight Week Data Evaluating...to be Presented - Gilead Sciences (Nasdaq:GILD...include data from a 48-week analysis...Germany, will present 48-week safety and...Cheng, MD, PhD, Gilead Sciences, will...
Gilead Sciences Announces Acceptance of Study 934 Late Breaker Abstract at 44th Annual ICAAC in Washington, DC.
Business Wire; Sep 29, 2004; 700+ Words ...release reads: GILEAD SCIENCES ANNOUNCES ACCEPTANCE...be Presented Gilead Sciences (Nasdaq...presentation of 24-week interim data...extended to 96 weeks, with a 48-week primary...London, will present 24-week safety...release issued by Gilead on ...
Gilead Sciences Announces Results From Phase III Study of Adefovir Dipivoxil in Precore Mutant Chronic Hepatitis B Virus Infection.
Business Wire; Sep 19, 2001; 700+ Words ...Second Pivotal Study Gilead Sciences, Inc. (Nasdaq:GILD...10 mg once daily for 48 weeks is associated with improvements...endpoint in this study. Gilead expects to present these data in detail...placebo (n=62) for 48 weeks. To further evaluate...
Gilead Sciences Announces Preliminary Results From Phase III Study of Investigational Anti-HIV Agent Tenofovir DF.
Business Wire; Feb 20, 2001; 700+ Words ...Pivotal Study Gilead Sciences, Inc. (Nasdaq...from an ongoing 48-week pivotal...experienced patients. Gilead expects to present these data in...907 Design The 48-week study enrolled...at least eight weeks prior to entering...
Gilead Announces Preliminary 48-Week Data From Study 934 Comparing Viread and Emtriva to Combivir Both in Combination With Sustiva in Patients With HIV.
Business Wire; Feb 3, 2005; 700+ Words ...Calif. -- Gilead Sciences (Nasdaq:GILD...announced preliminary 48-week data from the company...copies/mL at 48 weeks, based on the...endpoint is at 48 weeks. The prespecified...respectively. Gilead expects to present these data at a...
Gilead Presents Clinical Data Demonstrating That 60 mg PREVEON is as Effective as 120 mg for HIV Infection With Improved Safety Profile.
Business Wire; Mar 19, 1999; 700+ Words ...Receiving 60 mg Dose Gilead Sciences, Inc. (Nasdaq...in Study 417 This 48-week, double-blind...copies/mL) at week 20, the primary...2 log10 after 20 weeks. Similar changes...the completion of 48 weeks of therapy...
AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES GILEAD PRESENTS COMBINATION HEPSERA, LAMIVUDINE DATA.(drug development and approval)
BIOWORLD Today; Nov 5, 2002; ; 700+ Words Gilead Sciences Inc. reported 48-week results from Study 461, a trial to...and serological improvements through 48 weeks. Patients who received Hepsera alone...therapy. Complete data from a 12-week dose-ranging study showed that groups...
Gilead Announces Preliminary Results from 48-Week Phase III Study of Emtricitabine in Patients with Chronic Hepatitis B.
Business Wire; Nov 25, 2003; 700+ Words ...2003 Gilead Sciences, Inc. (Nasdaq...once daily for 48 weeks is associated...in this study. Gilead expects to present these data in...next year. "Gilead is dedicated to...FTCB-301 is a 48-week, double-blind...
Gilead's Combination HIV Drug, Truvada, Wins FDA Clearance.(Gilead Sciences Inc.)
BIOWORLD Today; Aug 4, 2004; ; 700+ Words ...combination of Gilead Sciences Inc.'s anti...Calif.-based Gilead, told BioWorld...will help the Gilead franchise. By...reported last week, Gilead said sales of...PI) for 24 to 48 weeks in ongoing clinical...not expected to present significant competition...
GILEAD PREPS FOR PANEL MEETING WITH POSITIVE PHASE III RESULTS.(for Viread)
BIOWORLD Today; Sep 26, 2001; ; 700+ Words ...Viread, a Gilead Sciences Inc. once-daily...advisory panel next week. Viread (tenofovir...On Tuesday, Gilead, of Foster City...information released by Gilead deals with the...Amy Flood, Gilead's manager of...is scheduled to present its new drug application...for a period of ...
Gilead's Combo Beats Glaxo Pill At 24-Week Study Mark.
BIOWORLD Today; Nov 3, 2009; 700+ Words ...ever-tricky science of beating HIV, Gilead Sciences Inc. said the...approved a few weeks ago as Truvada...back now." Gilead's stock (NASDAQ...42. The 24-week data are from...open-label, 48-week trial...once daily. Gilead is carrying out...Gilead expects to ...
GILEAD'S DRUG FOR CO-INFECTED HBV, HIV STRONG IN PILOT STUDY.(Brief Article)
BIOWORLD Today; Sep 5, 2001; ; 700+ Words Gilead Sciences Inc.'s adefovir...0.0001) at 48 weeks. "It's about...Calif.-based Gilead, acknowledged...what pattern, Gilead said. No HBV...up during the 48 weeks of treatment...Gilead will present more complete...
GAINS FROM TAMIFLU STOCKPILE, TOO? GILEAD'S COMBO BEATS GLAXO PILL AT 24-WEEK STUDY MARK By Randall Osborne West Coast Editor.
BIOWORLD Today; Aug 27, 2004; 700+ Words ...ever-tricky science of beating HIV, Gilead Sciences Inc. said the...approved a few weeks ago as Truvada...back now." Gilead's stock (NASDAQ...42. The 24-week data are from...open- label, 48-week trial...once daily. Gilead is carrying out...Gilead expects ...
Data From Study of Gilead's Adefovir Dipivoxil in Hepatitis B Patients With Lamivudine-Resistant Virus Presented At International Medical Meeting.
Business Wire; Apr 19, 2002; 700+ Words ...of the Liver Gilead Sciences (Nasdaq:GILD...levels through 16 weeks in patients infected...in the body. Gilead recently filed...Agency (EMEA). Gilead has requested...is an ongoing 48-week, randomized...resistance, were present in all patients...
39 results: 1 | 2

Find articles, research, and archives